KFF Poll: Three-in-Ten People Say They or Someone in Their Family Has Been Addicted to Opioids, with Rural Families Hit Hardest August 15, 2023 News Release A new KFF poll assessing the broad reach of the nation’s opioids crisis on families across the United States reveals that three-in-ten adults (29%) say they or someone in their family have ever been addicted to opioids, including prescription painkillers and illegal drugs like heroin. Rural residents (42%) and White…
KFF Health Tracking Poll July 2023: The Public’s Views Of New Prescription Weight Loss Drugs And Prescription Drug Costs August 4, 2023 Poll Finding About half of adults are interested in taking prescription weight loss drugs. though interest drops when presented with obstacles or drawbacks. Many adults struggle with affording prescription drugs and say there should be more price regulation. Few are aware of provisions in the 2023 Inflation Reduction Act aimed at lowering the drug price for Medicare beneficiaries
Poll: Nearly Half of Adults Would Be Interested in Prescription Weight-Loss Drugs, But Enthusiasm Fades Based on Lack of Coverage and Risk of Regaining Weight August 4, 2023 News Release Nearly half (45%) of the public are at least somewhat interested in taking a prescription weight-loss drug, including many who say they only want to lose a little weight, though many people lose interest when presented with potential financial and medical drawbacks, the latest KFF Health Tracking Poll reveals.The poll…
Key Facts About Medicare Part D Enrollment and Costs in 2023 July 26, 2023 Issue Brief The Medicare Part D program provides an outpatient prescription drug benefit to older adults and people with long-term disabilities in Medicare who enroll in private plans. This brief analyzes Medicare Part D enrollment and costs in 2023 and trends over time. The analysis highlights the substantial growth of Medicare Advantage drug plans in the marketplace for Part D drug coverage, where enrollment overall is concentrated in a handful of large plan sponsors.
What are the Implications of New Anti-Obesity Drugs for Racial Disparities? July 24, 2023 Blog This policy watch discusses some of the potential implications of the new anti-obesity drugs for racial equity.
10 Prescription Drugs Accounted for $48 Billion in Medicare Part D Spending in 2021, or More Than One-Fifth of Part D Spending That Year July 12, 2023 News Release A new KFF analysis finds that the 10 top-selling prescription drugs under Medicare Part D comprised less than 1 percent of all covered drugs in 2021, but accounted for 22 percent, or $48 billion, of gross Medicare Part D drug spending that year. The analysis provides context for understanding the…
A Small Number of Drugs Account for a Large Share of Medicare Part D Spending July 12, 2023 Issue Brief The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since 2018.
New Alzheimer’s Drugs Spark Hope for Patients and Cost Concerns for Medicare July 6, 2023 Blog The Food and Drug Administration granted full approval to Leqembi, a new Alzheimer’s drug, on July 6, 2023. This updated policy watch focuses on the implications of Medicare coverage of the drug for program spending as well as equity and affordability issues for beneficiaries, and the potential for the Inflation Reduction Act to address the spending impacts. It also covers additional details from the Centers for Medicare and Medicaid Services about patient registries.
June 14 Web Event: Probing the Power and Practices of Pharmacy Benefit Managers June 14, 2023 Event Pharmacy benefit managers (PBMs) are increasingly scrutinized intermediaries in the U.S. health care system, negotiating discounts on prescription medications for health insurers and employers while collecting rebates from drugmakers. Even as PBMs have taken on a larger role in drug coverage and pricing in recent decades, including through mergers with…
KFF Health Tracking Poll May 2023: Health Care in the 2024 Election and in the Courts May 26, 2023 Poll Finding Nearly a year after the Supreme Court overturned Roe v. Wade, this poll examines the public’s views of abortion and the Supreme Court, and knowledge about mifepristone, a medication abortion drug that is the subject of another court case, the ACA’s preventive services provision and HIV in the US.